More over, comparison of the progression-free survival rates of the negative expression (n=45) and positive expression (n=57) groups, shown in Figure4, revealed statistical significant difference in the progression-free survival rate between the two groups(P=0.054).Thus, the examination of CHD1L expression by IHC could be used as an additional tool in identifying those ovarian carcinoma patients at increased risk of tumor metastasis and/or having a worse prognosis. This evidence concerns the gene CHD1L and ovarian carcinoma.